Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -32.27% is in line with its 5-year average of -31.88%, near the high end of its 5-year range (-67.06%–-20.04%).
As of the fiscal period ended Tuesday, June 30, 2026. 22.32% below its 12-month average of -26.38%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -32.27%.
RETURN ON EQUITY (ROE)
-32.27%
RETURN ON EQUITY (ROE) AVG TTM
-26.38%
RETURN ON EQUITY (ROE) AVG 3Y
-31.08%
RETURN ON EQUITY (ROE) AVG 5Y
-31.88%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-22.32%
CURRENT VS 3Y AVG
-3.84%
CURRENT VS 5Y AVG
-1.24%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 725 covered companies
CURRENT VS SECTOR MEDIAN
+21.66%
vs the sector median at left
PROCEPT BioRobotics Corporation
Market Cap
$983.77M
Return on Equity (ROE)
-32.27%
TTM Avg
-26.38%
3Y Avg
-31.08%
5Y Avg
-31.88%
Market Cap
$981.54M
Return on Equity (ROE)
36.64%
TTM Avg
876.73%
3Y Avg
395.64%
5Y Avg
252.56%
Market Cap
$978.33M
Return on Equity (ROE)
-25.78%
TTM Avg
29.18%
3Y Avg
31.59%
5Y Avg
31.59%
Market Cap
$971.97M
Return on Equity (ROE)
2.18%
TTM Avg
-5.89%
3Y Avg
-1.23%
5Y Avg
4.05%
Market Cap
$995.99M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$967.94M
Return on Equity (ROE)
-15.09%
TTM Avg
46.85%
3Y Avg
62.20%
5Y Avg
62.20%
Market Cap
$1.01B
Return on Equity (ROE)
-63.62%
TTM Avg
-41.08%
3Y Avg
-23.78%
5Y Avg
-22.76%
Market Cap
$949.90M
Return on Equity (ROE)
N/A
TTM Avg
80.91%
3Y Avg
80.91%
5Y Avg
80.91%
Market Cap
$949.84M
Return on Equity (ROE)
-96.97%
TTM Avg
-57.21%
3Y Avg
-47.20%
5Y Avg
-49.27%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $983.77M | -32.27% | -26.38% | -31.08% | -31.88% |
| MeiraGTx Holdings plc (MGTX)vs › | $981.54M | 36.64% | 876.73% | 395.64% | 252.56% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $978.33M | -25.78% | 29.18% | 31.59% | 31.59% |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.97M | 2.18% | -5.89% | -1.23% | 4.05% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $995.99M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $967.94M | -15.09% | 46.85% | 62.20% | 62.20% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | -63.62% | -41.08% | -23.78% | -22.76% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $949.90M | N/A | 80.91% | 80.91% | 80.91% |
| Savara Inc. (SVRA)vs › | $949.84M | -96.97% | -57.21% | -47.20% | -49.27% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -4.51% | -33.13% | -42.62% | -42.62% |
ROE
-32.3%
ROA
-22.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -32.27% |
| 2026-03-31 | -29.47% |
| 2025-12-31 | -26.12% |
| 2025-09-30 | -22.24% |
| 2025-06-30 | -21.81% |
| 2025-03-31 | -23.18% |
| 2024-12-31 | -22.73% |
| 2024-09-30 | -41.48% |
| 2024-06-30 | -41.19% |
| 2024-03-31 | -39.15% |
| 2023-12-31 | -37.72% |
| 2023-09-30 | -35.60% |
| 2023-06-30 | -67.06% |
| 2023-03-31 | -56.87% |
| 2022-12-31 | -44.22% |
| 2022-09-30 | -35.03% |
| 2022-06-30 | -28.77% |
| 2022-03-31 | -25.41% |
| 2021-12-31 | -22.41% |
| 2021-09-30 | -20.04% |
| 2021-03-31 | -86.90% |
